Jing Li

Founder and CEO VelaVigo

Dr Li is the founder and CEO of VelaVigo. Currently he has raised $160m, out-licensed two pre-clinical programs with more than $1200m deal value and developed two first-in-class programs into global clinical trials.
Prior to founding VelaVigo, he served as Senior Vice President in WuXi Biologics. Before joining WuXi Biologics, he worked in Novartis Biologics Center as Senior Manager of Portfolio & Alliance Management. Before that, he worked in Novartis Oncology as Lab Head and Program Team Head. Prior to Novartis, he worked in Wyeth (now Pfizer) as Senior Scientist and Project Leader.
Dr Li received his M.D. and Ph.D. degree in molecular immunology and oncology from Peking University Health Science Center (the former Beijing Medical University), and MBA degree from Yale University School of Management. He obtained his post-doctorate training in Tufts University.
Dr Li has 30+ years of professional experience in antibody engineering and 25 years of industry experience in drug discovery and development field. He is a member of AACR (American Association for Cancer Research), ASCO (American Society of Clinical Oncology) and FOCIS (Federation of Clinical Immunology Societies). He has filed 70+ patent applications and authored 20+ publications. His founding journey of VelaVigo has been adopted by Harvard Business School as a case study for its unique business model and innovative approach.

Seminars

Tuesday 9th March 2027
Showcasing Phase 1/2a Open-Label Clinical Trial Results Evaluating VBC103, a Nectin-4 & TROP2 Targeted Bi-Specific ADC in Participants with Advanced Solid Tumour Malignancies
5:15 pm
  • Leveraging an internal R&D engine for consistent delivery of ADC programmes
  • Designing a novel dual-targeting bispecific ADC that simultaneously targets Nectin-4 and TROP2
  • Showcasing Phase 1/2a open-label clinical trial results evaluating VBC103 in participants with advanced solid tumour malignancies
Jing Li - Velavigo